VRAX (Virax Biolabs Group) ROE % Adjusted to Book Value : -81.11% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group ROE % Adjusted to Book Value?

Virax Biolabs Group's ROE % for the quarter that ended in Sep. 2024 was -78.68%. Virax Biolabs Group's PB Ratio for the quarter that ended in Sep. 2024 was 0.97. Virax Biolabs Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -81.11%.

Virax Biolabs Group ROE % Adjusted to Book Value Historical Data

The historical data trend for Virax Biolabs Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group ROE % Adjusted to Book Value Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

ROE % Adjusted to Book Value

-113.47

-273.32

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-20.21	-100.65	-80.97	-384.53	-81.11

Competitive Comparison of Virax Biolabs Group's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Virax Biolabs Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's ROE % Adjusted to Book Value falls into.

Virax Biolabs Group ROE % Adjusted to Book Value Calculation

Virax Biolabs Group's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-92.93%	/	0.34
	=	-273.32%

Virax Biolabs Group's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-78.68%	/	0.97
	=	-81.11%

Virax Biolabs Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.